Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$6.11	$4.58	$3.21 ▼ $7.18	$1.47B	0.68	4.67 million shs	3.65 million shs
CAPR Capricor Therapeutics	$7.10 +1.3%	$8.58	$3.98 ▼ $23.40	$320.70M	0.59	1.78 million shs	888,772 shs
HROW Harrow	$39.12 +2.5%	$33.93	$20.85 ▼ $59.23	$1.41B	0.41	659,886 shs	618,433 shs
SPRY ARS Pharmaceuticals	$13.50 -9.2%	$16.80	$10.00 ▼ $18.90	$1.47B	0.9	1.80 million shs	3.13 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	0.00%	+2.35%	+39.18%	+53.90%	-4.08%
CAPR Capricor Therapeutics	+1.28%	-10.80%	+4.11%	-30.73%	+55.02%
HROW Harrow	+2.52%	+0.77%	+5.87%	+51.04%	-2.40%
SPRY ARS Pharmaceuticals	-9.21%	-7.09%	-25.00%	-9.88%	+0.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.3377 of 5 stars	3.5	2.0	4.4	3.0	2.5	0.6
CAPR Capricor Therapeutics	3.1012 of 5 stars	4.6	2.0	0.0	2.1	0.8	0.6
HROW Harrow	3.6792 of 5 stars	4.6	1.0	0.0	3.9	2.5	0.6
SPRY ARS Pharmaceuticals	2.7342 of 5 stars	3.6	0.0	0.0	2.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	3.00	Buy	$11.50	88.22% Upside
CAPR Capricor Therapeutics	3.11	Buy	$22.56	217.68% Upside
HROW Harrow	3.13	Buy	$64.67	65.30% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	129.63% Upside

Current Analyst Ratings Breakdown

Latest CAPR, ARDX, HROW, and SPRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	HROW Harrow	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/14/2025	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$62.00 ➝ $63.00
8/13/2025	HROW Harrow	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $64.00
8/6/2025	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/5/2025	ARDX Ardelyx	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
8/5/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $12.00
8/5/2025	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00 ➝ $14.00
7/14/2025	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/14/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $12.00
7/11/2025	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00
7/11/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$77.00 ➝ $24.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$333.61M	4.41	N/A	N/A	$0.58 per share	10.53
CAPR Capricor Therapeutics	$22.27M	14.58	N/A	N/A	$2.30 per share	3.09
HROW Harrow	$227.66M	6.36	$0.14 per share	279.07	$1.33 per share	29.41
SPRY ARS Pharmaceuticals	$89.15M	14.97	$0.01 per share	1,755.96	$1.95 per share	6.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.23	N/A	19.71	N/A	-14.60%	-36.57%	-13.42%	10/30/2025 (Estimated)
CAPR Capricor Therapeutics	-$40.47M	-$1.64	N/A	N/A	N/A	-181.71%	-62.71%	-50.82%	N/A
HROW Harrow	-$17.48M	-$0.25	N/A	97.80	N/A	-4.49%	-2.18%	-0.35%	N/A
SPRY ARS Pharmaceuticals	$8M	-$0.49	N/A	N/A	N/A	-42.74%	-21.85%	-15.88%	N/A

Latest CAPR, ARDX, HROW, and SPRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SPRY ARS Pharmaceuticals	-$0.41	-$0.46	-$0.05	-$0.46	$12.92 million	$15.72 million
8/11/2025	Q2 2025	CAPR Capricor Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$2.60 million	N/A
8/11/2025	Q2 2025	HROW Harrow	$0.01	$0.24	+$0.23	$0.13	$64.23 million	$63.74 million
8/4/2025	Q2 2025	ARDX Ardelyx	-$0.13	-$0.08	+$0.05	-$0.08	$82.69 million	$97.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.44	4.30	4.03
CAPR Capricor Therapeutics	N/A	4.37	4.37
HROW Harrow	0.78	0.62	0.58
SPRY ARS Pharmaceuticals	0.37	6.17	5.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
CAPR Capricor Therapeutics	21.68%
HROW Harrow	72.76%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
CAPR Capricor Therapeutics	10.50%
HROW Harrow	15.16%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	240.98 million	229.42 million	Optionable
CAPR Capricor Therapeutics	101	45.72 million	40.92 million	Optionable
HROW Harrow	180	37.00 million	31.39 million	Optionable
SPRY ARS Pharmaceuticals	90	98.83 million	65.72 million	Optionable

CAPR, ARDX, HROW, and SPRY Headlines

Recent News About These Companies

ARS Pharmaceuticals (NASDAQ:SPRY) CFO Sells 12,500 Shares

August 23 at 9:18 AM | insidertrades.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 2.3% Following Insider Selling

August 23 at 2:52 AM | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Insider Sells $173,186.32 in Stock

August 22 at 8:42 AM | insidertrades.com

Aberdeen Group plc Takes $12.61 Million Position in ARS Pharmaceuticals, Inc. $SPRY

August 21 at 4:18 AM | marketbeat.com

Equities Analysts Issue Forecasts for SPRY FY2025 Earnings

August 19, 2025 | marketbeat.com

Equities Analysts Offer Predictions for SPRY FY2025 Earnings

August 19, 2025 | americanbankingnews.com

Leerink Partnrs Issues Negative Forecast for SPRY Earnings

August 19, 2025 | marketbeat.com

Equities Analysts Offer Predictions for SPRY Q3 Earnings

August 19, 2025 | marketbeat.com

William Blair Issues Optimistic Forecast for SPRY Earnings

August 19, 2025 | americanbankingnews.com

Leerink Partnrs Issues Pessimistic Outlook for SPRY Earnings

August 19, 2025 | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS

August 15, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript

August 14, 2025 | msn.com

ARS Pharma Sales Jump 3,040% in Q2

August 14, 2025 | aol.comA

ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For

August 14, 2025 | finance.yahoo.com

ARS Pharmaceuticals Reports Strong Growth for neffy

August 14, 2025 | msn.com

ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2025 | zacks.com

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

August 13, 2025 | globenewswire.com

Earnings Outlook For ARS Pharmaceuticals

August 12, 2025 | benzinga.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 6.3% - Should You Sell?

August 12, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Holdings Raised by Levin Capital Strategies L.P.

August 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, ARDX, HROW, and SPRY Company Descriptions

Ardelyx NASDAQ:ARDX

$6.11 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.15 +0.04 (+0.64%)

As of 08/22/2025 07:58 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Capricor Therapeutics NASDAQ:CAPR

$7.10 +0.09 (+1.28%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.10 0.00 (-0.07%)

As of 08/22/2025 07:58 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Harrow NASDAQ:HROW

$39.12 +0.96 (+2.52%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$39.20 +0.08 (+0.20%)

As of 08/22/2025 07:47 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

ARS Pharmaceuticals NASDAQ:SPRY

$13.50 -1.37 (-9.21%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$13.54 +0.04 (+0.26%)

As of 08/22/2025 07:43 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time